IGC Pharma, Inc. (IGC)

[NetworkNewsWire]

IGC Submits International Patent Applications for IGC-501

India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced that it has filed patent applications for IGC-501 in Canada, Israel and Europe in support of its ongoing cannabis-based combination therapy development initiatives. “We continue to strengthen our IP position in cannabis-based combination therapies and have progressed to include global patent filings,” Ram Mukunda, CEO of IGC, stated in the news release. “IGC is committed to addressing high potential international markets as a first mover in this emerging segment of cannabis-based combination therapy pharmaceuticals.” IGC-501 is being developed to treat neuropathic pain, which represents a sizable and growing market. In September 2012, the Journal of Pain reported that the estimated national cost of pain ranges from $560 billion to $635 billion annually, with costs associated with the abuse of prescription opioids clocking in at roughly $25 billion.

To view the full press release, visit http://nnw.fm/WP7oF

About IGC

India Globalization Capital is engaged in the development of cannabis-based therapies to treat pain, PTSD, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions. In support of this mission, IGC has assembled a portfolio of patent filings for its phytocannabinoid-based treatments. The company is based in Bethesda, Maryland. For more information visit www.igcinc.us